European and US pharmaceutical supply chains are exhibiting a growing dependence on China and India for essential active pharmaceutical ingredients (APIs) and other critical starting materials. This heightened reliance presents a significant risk, as efforts to diversify sourcing from China to India may not fully address vulnerabilities, given India's own substantial dependence on Chinese inputs for its pharmaceutical production.
The current geopolitical landscape, coupled with trade tariffs and various supply chain disruptions, is compelling both pharmaceutical companies and governments to prioritize strategies that enhance resilience. This includes actively seeking alternative sourcing locations and developing more robust, diversified supply networks.
For freight forwarders and logistics professionals, this trend implies a continued need for meticulous risk assessment and contingency planning, especially for pharmaceutical shipments. The interconnectedness of supply chains between China and India means that disruptions in one region can quickly cascade, affecting the availability and lead times of critical pharma cargo. Forwarders should anticipate potential shifts in routing and increased demand for secure, temperature-controlled logistics solutions as companies strive to build more resilient supply chains. This could also lead to higher demand for multimodal solutions and warehousing in strategic locations to buffer against potential shocks.
